Indaptus Therapeutics raises $24M in private placement, shares climb
What's the deal? Indaptus TherapeuticsDealroom has a profile for this one. Try Dealroom → has entered a $24 million private placement, sending its shares higher, the company said in September 2026.
Why it matters? The raise ranks in the top 10% of private placements by amount over the past 48 months, based on a sample of 5,673 comparable deals. That marks it as a sizeable financing for the biotech.
The signal: Non-venture private placements remain a key funding route for small-cap biotechs, offering cash without the terms of a traditional venture round. Indaptus's raise — and the market's positive reaction — shows investors still have appetite for the model.
Read more: in.marketscreener.com
Image credit: Generated with Gemini
